Evaluation of Multi-Cancer Early Detection Testing in a High-Risk Population: The INFORM Study

Predisposition, Genetic Clinical Trial

Official title: Evaluation of Multi-Cancer Early Detection Testing in a High-Risk Population: The INFORM Study

Status Not yet recruiting

Clinical Trial Summary

The purpose of this research study is to evaluate the possible benefits and harms of screening with an investigational blood test designed to detect many types of cancer early.

The name of the screening blood test being studied is:

-GRAIL Galleri test

Clinical Trial Description

This is a prospective, interventional study to assess the use of the GRAIL's Galleri multi-cancer early detection (MCED) Test, an investigational blood test designed to detect many types of cancer, for participants that are considered at slightly higher than average risk of developing certain types of cancers. The test looks for small pieces of genetic material called deoxyribonucleic acid (DNA) in the blood that may indicate the presence of cancer.

The research study procedures include screening for eligibility, blood tests, questionnaires, and clinic visits.

Participation in this research study is expected to last up to 3 years.

It is expected that about 1,000 people will take part in this research study. ;

Related Conditions & MeSH terms

• Disease Susceptibility
• Genetic Predisposition to Disease
• Predisposition, Genetic

• NCT number: NCT06450171
• Study type: Interventional
• Source: Dana-Farber Cancer Institute
• Contact: Elizabeth ODonnell, MD
• Phone: 587-215-2361
• Email: elizabeth_odonnell@dfci.harvard.edu
• Status: Not yet recruiting
• Phase: N/A
• Start date: December 2024
• Completion date: January 31, 2028